Tandem obtains Health Canada approval for Trurapi U-100 compatibility with t:slim X2 pump

TANDEM DIABETES CARE INC

Health Canada approved adding Trurapi U-100 to compatible insulins list for t:slim X2 with Control-IQ in Canada.
Amended distributor agreement with Unomedical extends term and revises definitions, manufacturing, and purchase terms.
Amendment details to be filed in Q2 2024 10-Q; no financial impact disclosed.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TANDEM DIABETES CARE INC amended Amendment Number 1 with Unomedical a/s (effective 2024-05-10).

Action: amendment
Agreement: supply
Counterparty: Unomedical a/s
Effective: 2024-05-10

Exact text from the filing

On May 10, 2024, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) and Unomedical a/s, a Danish corporation and a subsidiary of the ConvaTec Group (“Unomedical”), entered into Amendment Number 1 (“Amendment 1”) to the Distributor Agreement, dated as of January 14, 2022, between the Company and Unomedical, under which Unomedical manufactures, tests, sterilizes and packs all of the infusion sets under the Company’s brands (the “Original Agreement”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-24-000088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.